Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2010

View Archived Issues

Exelixis claims novel mTOR and PI3K-alpha inhibitors

German scientists identify new cysteine protease inhibitors

Lilly identifies novel selective estrogen receptor modulators

Merck & Co. claims novel mGlu2 receptor agonists

Final data disclosed from PROTECT trial of PEG-IFN-alfa2b/ribavirin

HCV NS5B polymerase inhibitor ABT-072 shows promising safety and pharmacokinetics

Serum markers may identify children who will develop active multiple sclerosis

Greater HbA1c reductions with LY-2189265 in Hispanic patients with type 2 diabetes

Cancer cell stemness inhibitor BBI-608 safe and active in ongoing phase I trial

No endocrine safety concerns noted in phase II trials of ulipristal acetate for uterine fibroids

Amgen provides product and pipeline update for first quarter of 2010

ALN-RSV01 may benefit lung transplant patients with RSV infection

Santaris advances SPC-5001 into development to lower cholesterol

PAION and FDA agree on design phase IIb trial of CNS-7056

Biotie reports encouraging topline phase I data on ELB-353

Living Cell Technologies receives grant from JDRF for phase II DiabeCell trial

ViroPharma begins phase II trial of subcutaneous Cinryze in HAE

Cleveland BioLabs opens U.S. office of Incuron to develop anticancer curaxins

CHMP adopts positive opinion for variation to terms of Reyataz marketing authorization

Rosuvastatin gains new indication to prevent major cardiovascular events

Dynavax reports preclinical data on universal flu vaccine candidate

Logical Therapeutics begins phase IIb safety trial of naproxen etemesil

FDA clears NexMed's phase II PrevOnco trial in advanced unresectable hepatocellular cancer

Ophthotech enrolls first patient in phase II E-10030 trial in macular degeneration

Sirion Therapeutics launches Zirgan in U.S. for ocular herpes

TRACON starts phase I/II TRC-105 trial in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...